GEHC — GE HealthCare Technologies Inc.

GE HealthCare Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $5.1 billion, reflecting 2.9% organic growth year-over-year, at the high end of expectations.
• Adjusted EBIT Margin: 13.5%, down 150 basis points year-over-year, impacted by tariffs and supplier issues.
• Adjusted EPS: $0.99, including a $0.16 impact from tariffs.
• Free Cash Flow: $112 million, up $13 million year-over-year.
• Orders Growth: 1.1%, with a book-to-bill ratio of 1.07 and a record backlog of $21.8 billion, up $1.2 billion year-over-year.

2. Strategic Updates and Business Highlights

• Strong growth in pharmaceutical diagnostics, advanced visualization solutions, and imaging businesses.
• Notable advancements in product pipeline, including regulatory clearances for Photonova Spectra (Photon Counting CT) and new MRI technologies.
• Continued ramp-up of Flyrcado, with a nearly 80% increase in doses since January, and onboarding of new customers.
• Acquisition of Intelerad completed, aimed at enhancing cloud capabilities and driving recurring revenue.
• Organizational restructuring to create a new segment, Advanced Imaging Solutions (AIS), intended to sharpen focus and accelerate growth.

3. Forward Guidance and Outlook

• 2026 Organic Sales Growth Guidance: Maintained at 3% to 4%.
• Adjusted EBIT Margin Guidance: Revised to 15.4% to 15.7%, reflecting a cautious outlook due to inflation.
• Adjusted EPS Guidance: Reduced to $4.80 to $5.00 per share, indicating 5% to 9% growth year-over-year.
• Free Cash Flow Expectation: Approximately $1.6 billion for 2026.

4. Bad News, Challenges, or Points of Concern

• Profit performance was negatively impacted by a recall related to a PDx supplier, leading to a $0.05 EPS impact.
• Significant inflationary pressures, particularly from memory chips and oil/freight costs, totaling an estimated $250 million impact for the year.
• Decline in Patient Care Solutions (PCS) revenue by 8.1% year-over-year, attributed to large monitoring installations concentrated in the second half of the year.
• China revenue declined year-over-year, although sequential improvement was noted; cautious outlook remains.

5. Notable Q&A Insights

• Management expressed confidence in the capital equipment market and anticipated mid-single-digit revenue growth in the U.S. and double-digit growth in EMEA.
• The inflationary impact on EPS was discussed, with management indicating that the second quarter would reflect the highest inflationary costs, while mitigation measures would begin to benefit in the second half of the year.
• Concerns about competition from generics in the pharmaceutical diagnostics market were addressed, with management noting no current impact from new entrants.
• The strategic rationale behind the AIS segment was emphasized, with expectations for improved growth and efficiency in product development and customer engagement.

Overall, GE HealthCare reported solid revenue growth but faced challenges from inflation and operational issues, prompting a cautious outlook for the remainder of 2026. The company is optimistic about its innovation pipeline and strategic initiatives aimed at enhancing growth and profitability.